As a major pharmaceutical company that is constantly innovating and developing new treatments, Eli Lilly (NYSE: LLY) is ...

Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...

Eli Lilly ( LLY 0.86%) is a screaming buy because it makes the most potent weight-loss drug that's on the market right now, ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

If Trump wants to improve Americans’ health, as he says, expanding coverage of weight-loss drugs should be a priority. With ...

For the first time in a decade, obesity in the U.S. is declining — and a new study suggests it’s because of wildly popular ...

We recently compiled a list of the 16 Best Income Stocks To Buy According to Analysts. In this article, we are going to take ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 491.86% and ...

NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...

Additionally, Lilly CEO David Ricks said the drugmaker will start testing its GLP-1 medications as treatments for alcohol and ...